Tranexamic Acid in Intertrochanteric and Subtrochanteric Femur Fractures
Status:
Unknown status
Trial end date:
2017-03-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the effect of Tranexamic Acid (TXA) on blood loss
and need for perioperative blood transfusion following intertrochanteric and subtrochanteric
femur fractures. TXA is a antifibrinolytic medication that prevents the breakdown of blood
clots by inhibiting the activation of plasminogen to plasmin in the coagulation cascade. Our
hypothesis is that by providing TXA at the time of hospital admission it will decrease the
amount of preoperative and intraoperative bleeding thereby leading to a decreased need for
post-operative transfusion. This a double blinded, placebo controlled, therapeutic trial in
which half of patients will be randomized to receive TXA at the time of hospital admission
and half of patients will receive a placebo.